Raphaëlle Meunier1, Marie-Elise Truchetet1, Benjamin Dallaudière2, Claire Fournier2, Thomas Barnetche1, Nicolas Amoretti3, François Cornelis4, Olivier Hauger5. 1. Service de Rhumatologie, Hôpital Pellegrin, CHU Bordeaux, Bordeaux, France. 2. Service d'imagerie diagnostique et thérapeutique de l'adulte, Hôpital Pellegrin, CHU Bordeaux, Bordeaux, France. 3. Service d'imagerie, Hôpital Pasteur 2, Nice, France. 4. Service d'imagerie médicale, Hôpital Lariboisière, APHP, Paris, France. 5. Service d'imagerie diagnostique et thérapeutique de l'adulte, Hôpital Pellegrin, CHU Bordeaux, Bordeaux, France. olivier.hauger@chu-bordeaux.fr.
Abstract
OBJECTIVES: To evaluate MRI performance on both initial and long-term rheumatologic diagnosis of spondyloarthritis (SpA), taking into account clinical evolution and treatment response, and the impact of gadolinium injection. METHODS: In this single-center study, patients who underwent both spinal and sacroiliac (SI) joint MRI were prospectively recruited between May 2013 and January 2014 and followed for 7 years until 2020. Clinical, biological, and radiologic parameters were collected. At 7-year follow-up (2020), two independent readers reevaluated the initial MRI datasets for specific radiological features of SpA with a 5-point Likert scale to record the estimation of confidence. The centralized MRI interpretations were compared to the established rheumatologic diagnoses in 2013 and 2020. RESULTS: In total, 145 patients (52 men and 93 women) were included. During the 7-year follow-up, the number of patients with positive SpA diagnosis decreased from 93 to 58. Mean sensitivity, specificity, and accuracy of non-contrast MRI were 18, 97, and 49% and 27, 97, and 69% considering 2013 and 2020 rheumatologic diagnoses, respectively. Mean sensitivity, specificity, and accuracy values of gadolinium-enhanced MRI were 26, 97, and 54% and 38, 97, and 73% considering 2013 and 2020 diagnoses, respectively. Post-contrast MRI enabled identification of a subgroup of enthesis-only lesions, without any bone lesions, corresponding to 14% of the pathological cohort. It confirmed uncertain diagnoses in an additional 8.5% of pathological cases. CONCLUSIONS: MRI performance for SpA diagnosis is higher when long-term clinical follow-up is considered than when compared to initial diagnosis. Gadolinium injection increases MRI diagnostic performance and may demonstrate a pure enthesic form of the disease, without bone abnormality. KEY POINTS: • Compared to the rheumatologist's diagnosis over long-term clinical follow-up, MRI performance for SpA is higher than usually estimated. • Gadolinium injection increases diagnostic performance of MRI as it may identify a purely enthesis form of the disease. • Gadolinium injection should be discussed in patients for whom the diagnostic suspicion is strong and whose initial non-injected examination is normal or doubtful.
OBJECTIVES: To evaluate MRI performance on both initial and long-term rheumatologic diagnosis of spondyloarthritis (SpA), taking into account clinical evolution and treatment response, and the impact of gadolinium injection. METHODS: In this single-center study, patients who underwent both spinal and sacroiliac (SI) joint MRI were prospectively recruited between May 2013 and January 2014 and followed for 7 years until 2020. Clinical, biological, and radiologic parameters were collected. At 7-year follow-up (2020), two independent readers reevaluated the initial MRI datasets for specific radiological features of SpA with a 5-point Likert scale to record the estimation of confidence. The centralized MRI interpretations were compared to the established rheumatologic diagnoses in 2013 and 2020. RESULTS: In total, 145 patients (52 men and 93 women) were included. During the 7-year follow-up, the number of patients with positive SpA diagnosis decreased from 93 to 58. Mean sensitivity, specificity, and accuracy of non-contrast MRI were 18, 97, and 49% and 27, 97, and 69% considering 2013 and 2020 rheumatologic diagnoses, respectively. Mean sensitivity, specificity, and accuracy values of gadolinium-enhanced MRI were 26, 97, and 54% and 38, 97, and 73% considering 2013 and 2020 diagnoses, respectively. Post-contrast MRI enabled identification of a subgroup of enthesis-only lesions, without any bone lesions, corresponding to 14% of the pathological cohort. It confirmed uncertain diagnoses in an additional 8.5% of pathological cases. CONCLUSIONS: MRI performance for SpA diagnosis is higher when long-term clinical follow-up is considered than when compared to initial diagnosis. Gadolinium injection increases MRI diagnostic performance and may demonstrate a pure enthesic form of the disease, without bone abnormality. KEY POINTS: • Compared to the rheumatologist's diagnosis over long-term clinical follow-up, MRI performance for SpA is higher than usually estimated. • Gadolinium injection increases diagnostic performance of MRI as it may identify a purely enthesis form of the disease. • Gadolinium injection should be discussed in patients for whom the diagnostic suspicion is strong and whose initial non-injected examination is normal or doubtful.
Authors: Rosaline van den Berg; Manouk de Hooge; Floris van Gaalen; Monique Reijnierse; Tom Huizinga; Désirée van der Heijde Journal: Rheumatology (Oxford) Date: 2013-05-06 Impact factor: 7.580
Authors: Désirée van der Heijde; Joachim Sieper; Walter P Maksymowych; Maxime Dougados; Rubén Burgos-Vargas; Robert Landewé; Martin Rudwaleit; Jürgen Braun Journal: Ann Rheum Dis Date: 2011-06 Impact factor: 19.103
Authors: Rosaline van den Berg; Grégory Lenczner; Fabrice Thévenin; Pascal Claudepierre; Antoine Feydy; Monique Reijnierse; Alain Saraux; Alain Rahmouni; Maxime Dougados; Désirée van der Heijde Journal: Ann Rheum Dis Date: 2014-06-24 Impact factor: 19.103
Authors: Nigil Haroon; Robert D Inman; Thomas J Learch; Michael H Weisman; MinJae Lee; Mohammad H Rahbar; Michael M Ward; John D Reveille; Lianne S Gensler Journal: Arthritis Rheum Date: 2013-10
Authors: J Sieper; M Rudwaleit; X Baraliakos; J Brandt; J Braun; R Burgos-Vargas; M Dougados; K-G Hermann; R Landewé; W Maksymowych; D van der Heijde Journal: Ann Rheum Dis Date: 2009-06 Impact factor: 19.103
Authors: Robert G W Lambert; Pauline A C Bakker; Désirée van der Heijde; Ulrich Weber; Martin Rudwaleit; K G Hermann; Joachim Sieper; Xenofon Baraliakos; Alex Bennett; Jürgen Braun; Rubén Burgos-Vargas; Maxime Dougados; Susanne Juhl Pedersen; Anne Grethe Jurik; Walter P Maksymowych; Helena Marzo-Ortega; Mikkel Østergaard; Denis Poddubnyy; Monique Reijnierse; Filip van den Bosch; Irene van der Horst-Bruinsma; Robert Landewé Journal: Ann Rheum Dis Date: 2016-01-14 Impact factor: 19.103
Authors: Kay-Geert A Hermann; Xenofon Baraliakos; Désirée M F M van der Heijde; Anne-Grethe Jurik; Robert Landewé; Helena Marzo-Ortega; Mikkel Østergaard; Martin Rudwaleit; Joachim Sieper; Jürgen Braun Journal: Ann Rheum Dis Date: 2012-05-14 Impact factor: 19.103
Authors: P Mandl; V Navarro-Compán; L Terslev; P Aegerter; D van der Heijde; M A D'Agostino; X Baraliakos; S J Pedersen; A G Jurik; E Naredo; C Schueller-Weidekamm; U Weber; M C Wick; P A C Bakker; E Filippucci; P G Conaghan; M Rudwaleit; G Schett; J Sieper; S Tarp; H Marzo-Ortega; M Østergaard Journal: Ann Rheum Dis Date: 2015-04-02 Impact factor: 19.103
Authors: Liesbeth Heuft-Dorenbosch; René Weijers; Robert Landewé; Sjef van der Linden; Désirée van der Heijde Journal: Arthritis Res Ther Date: 2006 Impact factor: 5.156